Dr. Reddy's Laboratories Limited (RDY) 6-K Current report (foreign)

Exhibit 99.4

  THE SKYVIEW 10 18th Floor, “NORTH LOBBY” Survey No. 83/1, Raidurgam Hyderabad - 500 032, India   Tel : +91 40 6141 6000

Independent Auditor’s Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to

The Board of Directors

Dr. Reddy’s Laboratories Limited

1. We have reviewed the accompanying “Statement of Unaudited Standalone Financial Results for the quarter and nine months ended 31 December, 2024” (the “Statement”) of Dr. Reddy’s Laboratories Limited (the “Company”) attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the “Listing Regulations”).

2. The Company’s Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) “Interim Financial Reporting” prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company’s Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, “Review of Interim Financial Information Performed by the Independent Auditor of the Entity” issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards (‘Ind AS’) specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S.R. BATLIBOI & ASSOCIATES LLP

Chartered Accountants

ICAI Firm registration number: 101049W/E300004

per Shankar Srinivasan
Partner
Membership No.:213271
UDIN: 25213271BMISLA4490
Place: Hyderabad
Date: January 23, 2025

S.R. Batliboi & Associates LLP, a Limited Liability Partnership with LLP Identity No. AAB-4295

Regd. Office : 22, Camac Street, Block ‘B’, 3rd Floor, Kolkata-700 016

  Dr. Reddy’s Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN : L85195TG1984PLC004507   Tel       : +91 40 4900 2900 Fax      : +91 40 4900 2999 Email  : mail@drreddys.com www.drreddys.com

DR. REDDY'S LABORATORIES LIMITED

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2024

								All amounts in Indian Rupees millions
			Quarter ended									Nine months ended						Year ended
Sl. No.		Particulars	31.12.2024			30.09.2024			31.12.2023			31.12.2024			31.12.2023			31.03.2024
			(Unaudited)			(Unaudited)			(Unaudited)			(Unaudited)			(Unaudited)			(Audited)
	1	Revenue from operations
		a) Sales		47,775			58,534			40,389			164,385			142,460			192,764
		b) License fees and service income		2,203			8,254			442			10,620			763			1,277
		c) Other operating income		172			175			199			520			567			797
		Total revenue from operations		50,150			66,963			41,030			175,525			143,790			194,838
	2	Other income		2,354			2,076			2,276			6,287			6,651			8,623
		Total income (1 + 2)		52,504			69,039			43,306			181,812			150,441			203,461
	3	Expenses
		a) Cost of materials consumed		10,117			9,343			8,187			28,571			23,838			32,915
		b) Purchase of stock-in-trade		5,084			6,565			5,569			19,052			14,403			19,866
		c) Changes in inventories of finished goods, work-in-progress and stock-in-trade		(370	)		(930	)		(651	)		(2,561	)		(1,868	)		(2,388	)
		d) Employee benefits expense		7,944			8,401			7,823			24,904			23,062			30,857
		e) Depreciation and amortisation expense		2,651			2,600			2,464			7,749			7,294			9,756
		f) Impairment of non current assets, net		-			-			-			-			-			260
		g) Finance costs		433			284			56			788			159			218
		h) Other expenses		15,451			16,368			13,539			46,568			39,032			54,064
		Total expenses		41,310			42,631			36,987			125,071			105,920			145,548
	4	Profit before tax (1 + 2 - 3)		11,194			26,408			6,319			56,741			44,521			57,913
	5	Tax expense/(benefit)
		a) Current tax		2,563			7,033			1,569			14,262			10,916			13,618
		b) Deferred tax		137			554			(2	)		992			533			875
	6	Net profit for the period/year (4 - 5)		8,494			18,821			4,752			41,487			33,072			43,420
	7	Other comprehensive income
		a) (i) Items that will not be reclassified to profit or loss		-			-			(8	)		-			(6	)		21
		(ii) Income tax relating to items that will not be reclassified   to profit or loss		-			-			-			-			-			(7	)
		b) (i) Items that will be reclassified to profit or loss		(779	)		(88	)		24			(812	)		(257	)		(446	)
		(ii) Income tax relating to items that will be reclassified to  profit or loss		196			22			(6	)		204			65			114
		Total other comprehensive (loss)/income		(583	)		(66	)		10			(608	)		(198	)		(318	)
	8	Total comprehensive income (6 + 7)		7,911			18,755			4,762			40,879			32,874			43,102
	9	Paid-up equity share capital (face value Re. 1/- each)		834			834			834			834			834			834
	10	Other equity																	241,574
	11	Earnings per equity share (face value Re. 1/- each)
		Basic		10.20			22.60			5.71			49.81			39.76			52.19
		Diluted		10.18			22.56			5.70			49.73			39.69			52.09
				(Not annualised)			(Not annualised)			(Not annualised)			(Not annualised)			(Not annualised)

See accompanying notes to the financial results.

   

 

DR. REDDY'S LABORATORIES LIMITED

Segment information								All amounts in Indian Rupees millions
		Quarter ended									Nine months ended						Year ended
Sl. No.	Particulars	31.12.2024			30.09.2024			31.12.2023			31.12.2024			31.12.2023			31.03.2024
		(Unaudited)			(Unaudited)			(Unaudited)			(Unaudited)			(Unaudited)			(Audited)
	Segment wise revenue and results
1	Segment revenue
	a) Pharmaceutical Services and Active Ingredients		8,272			7,972			7,658			24,764			20,900			30,742
	b) Global Generics		42,401			61,467			35,726			156,315			129,399			173,405
	c) Others		1,281			23			66			1,365			325			678
	Total		51,954			69,462			43,450			182,444			150,624			204,825
	Less: Inter-segment revenue		1,804			2,499			2,420			6,919			6,834			9,987
	Total revenue from operations		50,150			66,963			41,030			175,525			143,790			194,838
2	Segment results
	Profit/(loss) before tax and interest from each segment
	a) Pharmaceutical Services and Active Ingredients		313			(146	)		(397	)		97			(1,533	)		(287	)
	b) Global Generics		8,268			26,800			6,832			54,735			45,498			57,670
	c) Others		1,255			20			198			1,372			297			536
	Total		9,836			26,674			6,633			56,204			44,262			57,919
	Less: (i) Finance costs		433			284			56			788			159			218
	(ii) Other un-allocable (income)/expenditure, net		(1,791	)		(18	)		258			(1,325	)		(418	)		(212	)
	Total profit before tax		11,194			26,408			6,319			56,741			44,521			57,913

Global Generics includes operations of Biologics business. Inter-segment revenue represents sale from Pharmaceutical Services and Active Ingredients to Global Generics at cost.

Segmental capital employed

As certain assets of the Company including manufacturing facilities, development facilities and treasury assets and liabilities are often deployed interchangeably across segments, it is impractical to allocate these assets and liabilities to each segment. Hence, the details for capital employed have not been disclosed in the above table.

Notes:

1 The above statement of unaudited standalone financial results of Dr. Reddy's Laboratories Limited ("the Company"), which have been prepared in accordance with the Indian Accounting Standards (''Ind AS'') prescribed under Section 133 of the Companies Act, 2013 ("the Act'') read with relevant rules issued thereunder, other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India ("SEBI'') were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meetings held on 23 January 2025. The Statutory Auditors have carried out a limited review on the unaudited standalone financial results and issued unmodified report thereon.

2 "License fees and service income" for the quarter and nine months ended 31 December 2024 includes an amount of Rs.1,266 million received as a milestone payment upon U.S.FDA approval of DFD 29, in accordance with the license and collaboration agreement dated 29 June 2021 with Journey Medical Corporation. This transaction pertains to the Company’s Others segment.

3 "Other income" for the year ended 31 March 2024 includes: a) Rs.540 million recognised in April 2023, pursuant to settlement agreement with Janssen Group, in settlement of the claim brought in the Federal Court of Canada by the Company and its affiliates for damages under section 8 of the Canadian Patented Medicines (Notice of Compliance) Regulations in regard to the Company’s ANDS for a generic version of Zytiga®(Abiraterone).This transaction pertains to the Company's Global Generics segment. b) Dividend income of Rs. 445 million recognised in June 2023, declared by Kunshan Rotan Reddy Pharmaceutical Company Limited, joint venture of the company.

4 During the quarter and nine months ended 31 December 2024, an amount of Rs.834 million and Rs.2,534 million, respectively and during the quarter and nine months ended 31 December 2023, an amount of Rs.1,142 million and Rs.3,405 million, respectively, representing government grants has been accounted as a reduction from cost of materials consumed.

5 Pursuant to the amendment in The Finance Act 2024, resulting in withdrawal of indexation benefit on long-term capital gain, the company has written off Deferred Tax Asset amounting to Rs. 482 million, created in earlier periods on land, during the nine months ended 31 December 2024.

6 Agreement with Nestle India: On 25 April 2024, the Company entered into an agreement with Nestlé India Limited ("Nestlé India") for the manufacturing, development, promotion, marketing, sale, distribution, and commercialization of nutraceutical products and supplements in India, as well as other mutually agreed geographies. These operations will be carried out by Dr. Reddy's Nutraceuticals Limited, established on 14 March 2024. The entity was later renamed as Dr. Reddy's and Nestlé Health Science Limited (the “Nutraceuticals subsidiary”) on 13 June 2024.

Upon completion of the closing conditions, the transaction concluded on 01 August 2024. Consequently, the Company has made an additional investment of Rs. 7,340 million in its Nutraceuticals subsidiary, with corresponding infusion from Nestlé India amounting to Rs. 7,056 million resulting in a revised shareholding pattern of 51:49 between the Company and Nestlé India.

Further, the Company also received Rs. 8,113 million (excluding GST) as consideration towards transfer of its nutraceutical and vitamins, minerals, herbals, and supplements portfolio to Nutraceuticals subsidiary as part of the definitive agreement. This has been recorded as License fees for the nine months ended 31 December 2024. This acquisition pertains to Company’s Global Generics segment.

   

 

DR. REDDY'S LABORATORIES LIMITED

7 The Board of Directors of the Company at their meeting held on 27 July 2024 have approved the sub-division/ split of each equity share having a face value of Rupees five each, fully paid-up, into five equity shares having a face value of Rupee One each, fully paid-up (the “stock split”), by alteration of the capital clause of the Memorandum of Association of the Company. Further, each American Depositary Share (ADS) of the Company will continue to represent one underlying equity share as at present and, therefore, the number of ADSs held by an American Depositary Receipt(ADR) holder would consequently increase in proportion to the increase in number of equity shares. On 12 September 2024, the approval of the shareholders of the Company was obtained through a postal ballot process with a requisite majority.

Consequently w.e.f. record date of 28 October 2024, the authorized share capital, the paid up share capital and the treasury shares were sub-divided into five equity shares having a face value of Rupee One each. As on 31 December 2024, the closing number of shares fully paid up and treasury shares were 834,423,960 and 1,302,980 respectively.

Post stock split, the number of each stock option vested and unvested and not exercised as on the record date were sub-divided into five options and the exercise price was proportionately adjusted.

The effect of stock split was considered in the computation of basic and diluted EPS for the quarter and nine months ended 31 December 2024 and prior periods have been restated considering face value of Rupee One each in accordance with Ind AS 33- "Earnings per Share" and rounded off to the nearest decimals.

8 The Company considered the uncertainties relating to the escalation of conflict in the middle east, and duration of military conflict between Russia and Ukraine, in assessing the recoverability of receivables, goodwill, intangible assets, investments and other assets. For this purpose, the Company considered internal and external sources of information up to the date of approval of these financial results. Based on its judgments, estimates and assumptions, the Company expects to fully recover the carrying amount of receivables, goodwill, intangible assets, investments and other assets. The Company will continue to closely monitor any material changes to future economic conditions.

9 The Company received an anonymous complaint in September 2020, alleging that healthcare professionals in Ukraine and potentially in other countries were provided with improper payments by or on behalf of the Company in violation of U.S. anti-corruption laws, specifically the U.S. Foreign Corrupt Practices Act. The Company disclosed the matter to the U.S. Department of Justice (“DOJ”), Securities and Exchange Commission (“SEC”) and Securities Exchange Board of India. The Company engaged a U.S. law firm to conduct the investigation at the instruction of a committee of the Company’s Board of Directors. On 06 July 2021, the Company received a subpoena from the SEC for the production of related documents, which were provided to the SEC.

The Company has continued to engage with the SEC and DOJ, including through submissions and presentations regarding the initial complaint and additional complaints relating to other markets, and in relation to its Global Compliance Framework, which includes enhancement initiatives undertaken by the Company, and the Company is complying with its listing obligations as it relates to updating the regulatory agencies. While the findings from the aforesaid investigations could result in government or regulatory enforcement actions against the Company in the United States and/or foreign jurisdictions and can also lead to civil and criminal sanctions under relevant laws, the outcomes, including liabilities, are not reasonably ascertainable at this time.

	By order of the Board
	For Dr. Reddy's Laboratories Limited
Place: Hyderabad	G V Prasad
Date: 23 January 2025	Co-Chairman & Managing Director